Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by mcarter4on Dec 17, 2003 3:42pm
520 Views
Post# 6793772

RE: stock price:sj

RE: stock price:sjTo me ONC's price fall is simple and primarily due to: a) BT announcement of no trial NR's until Q1 2004 (although someone disputed the Q1); fall in price pretty much started then (why hold a risky bio when NR could be 2-5 months away) b) YE effect: big winners want to lock in, losers want tax losses (I see continued selling pressure until this is over) c) BT as CEO: seems almost incapable of acting as you would wish a CEO to, much better as Chief Lab Guy. Largely irrelevant a) BT selling shares; although it is a sad, sad statement about the CEO himself (he prefers NRM to ONC wow, should we also prefer NRM to ONC, hey maybe that's why NRM is going up and ONC going down). b) patents; particularly those not directly related to Reolysin c) NCI; Lor, Ingn, etc. seem not to have much premium related to NCI involvement, expect same for ONC d) everything else not directly related to trials being run by ONC or a potential partnership (if one ever occurs). What I'm trying to figure out is when to buy in before YE, and when to sell in first couple of weeks in January, as late Dec tax selloffs always seem to have a nice pop in the first couple of weeks.
Bullboard Posts